Patient-Perceived Utility of ctDNA Testing and Dimension of Well-Being: Results from BESPOKE CRC
Experts discuss how real-world data counter concerns that ctDNA testing increases patient anxiety, highlighting that most patients feel more reassured and confident in their care when receiving personalized ctDNA results, which supports its integration into routine surveillance to improve both clinical decision-making and patient quality of life.
One common critique from some clinicians is the concern that circulating tumor DNA (ctDNA) testing might increase patient anxiety. The fear is that a positive result or ongoing monitoring could cause distress or uncertainty. However, real-world data challenge this assumption. Results of an extensiveA large survey conducted with overof more than 1,700 patients across multiple cancer stages offers valuable insight into the patient experience with ctDNA testing. Rather than increasing anxiety, 73% of respondents reported that receiving their ctDNA results actually reduced their worry about cancer recurrence. This reduction in anxiety likely stems from the clarity and reassurance that the test provides, helping patients feel more informed about their health status.
Beyond anxiety reduction, ctDNA testing strengthensappears to strengthen patients’ confidence in their treatment plans. In the same survey, 87% of patients expressed that the information gained from ctDNA testing made them feel they were receiving the appropriate therapy. This trust in their care team is crucial for patient adherence and overall well-being, as feeling confident in treatment decisions can improve emotional health during a difficult journey. Moreover, 92% of patients indicated a desire to continue ctDNA testing for ongoing cancer surveillance, reflecting a strong acceptance and perceived value of this monitoring approach.
Most strikingly, 96% of patients valued the additional information provided by ctDNA testing, highlighting its importance beyond traditional markers and scans. This overwhelming positive response suggests that patients appreciate having more precise and personalized data about their disease status. Rather than adding stress, ctDNA testing empowers patients by giving them actionable insights, enhancing their sense of control and engagement in their care. Overall, these findings support the integration of ctDNA testing into routine surveillance, as it not only aids clinical decision-making but also improves patient experience and quality of life.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
